EC Number   |
Recommended Name  |
Application |
|---|
    1.1.1.100 | 3-oxoacyl-[acyl-carrier-protein] reductase |
drug development |
the enzyme has no isoforms and thus is a good target for inhibitor design |
| 1.1.1.100 | 3-oxoacyl-[acyl-carrier-protein] reductase |
drug development |
FabG is the antibacteria target of maple leaf extracts and tannic acid, and both reversible and irreversible inhibitions of FabG are important for the antibacterial effect |
| 1.1.1.100 | 3-oxoacyl-[acyl-carrier-protein] reductase |
drug development |
galangal extract inhibits FabG, thereby displaying antibacterial ability |
| 1.1.1.141 | 15-hydroxyprostaglandin dehydrogenase (NAD+) |
drug development |
induction of 15-hydroxyprostaglandin dehydrogenase expression or utilization of 15-keto-PGE2 analogue may have therapeutic benefits for the treatment of endotoxin-associated liver inflammation/injury |
| 1.1.1.146 | 11beta-hydroxysteroid dehydrogenase |
drug development |
isozyme 11beta-HSD1 is a target in treatment of metabolic diseases such as diabetes mellitus type 2 or obesity |
| 1.1.1.146 | 11beta-hydroxysteroid dehydrogenase |
drug development |
11beta-HSD1 will significantly contribute to the biotransformation of oracin in humans. The microsomal carbonyl reductase has a great potential to significantly impair the chemotherapy with the anticancer drug oracin |
| 1.1.1.184 | carbonyl reductase (NADPH) |
drug development |
CBR1 inhibition can improve the therapeutic response to doxorubicin and reduce its side effects |
| 1.1.1.184 | carbonyl reductase (NADPH) |
drug development |
the cardioprotectant 7-monohydroxyethylrutoside inhibits CBR1 activity. CBR1 V88I genotype status and the type of anthracycline substrate dictate the inhibition of CBR1 activity. Inhibition of CBR1 activity shall be considered during the development of novel cardioprotectants against anthracycline-related cardiotoxicity |
| 1.1.1.188 | prostaglandin-F synthase |
drug development |
prostaglandin formation is a key component of PGaction and the specific target of non-steroidal anti-inflammatory drugs |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
the enzyme is a potential therapeutic target, and the NAD+ site may be an exploitable target for the design of antimicrobial drugs |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
the enzyme is a target for drug development in treatment of structural schizophrenia |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
the enzyme is a target for therapeutic drugs |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
the enzyme is a target in enzyme-pattern-targeted chemotherapy in acuet leukemia, AML, treatment |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
the enzyme is a target in parasite treatment and elimination |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
the IMPDH-1 is an antiangiogenic drug target |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
1,2,3-triazole IMPDH inhibitors provide new tools for elucidating the role of IMPDH in Cryptosporidium parvum and may serve as potential therapeutics for treating cryptosporidiosis |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
at therapeutic concentrations in organ transplant patients, the effect of mycophenolic acid-acyl-glucuronide on IMPDHII activity is minimal compared to mycophenolic acid, and the quantification of mycophenolic acid metabolites for mycophenolate therapeutic drug monitoring and dose adjustment will be of no benefit |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
differences between the human and Mycobacterium tuberculosis IMPDHs in the region of binding of nucleotide inhibitors on the inosine 5'-phosphate binding site. These and other differences, may be exploited for the design of new inhibitors with selectivity against Mycobacterium tuberculosis IMPDH |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
IMPDH2 is the major target for cancer chemotherapy |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
Roche total mycophenolic acid assay (a new inosine monophosphate dehydrogenase inhibition assay) is a promising alternative for mycophenolic acid quantification where chromatographic methods are not available |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
type I IMPDH is identified as an antiangiogenic drug target. Inhibition may cause endothelial cell cycle arrest |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
IMPDH from Mycobacterium tuberculosis (MtIMPDH) is a potential molecular target to inhibitor development |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
inosine 5'-monophosphate dehydrogenase 2 (IMPDH2) from Mycobacterium tuberculosis is an attractive drug target |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
the enzyme IMPDH is a promising target for the treatment of Cryptosporidium infections |
| 1.1.1.205 | IMP dehydrogenase |
drug development |
the inhibition of IMPDH (leading to reduced cellular levels of guanine nucleotides) is an important strategy for antiproliferative, antiviral and antiparasitic effects. It is also a useful strategy for producing immunosuppression as IMPDH-dependent de novo synthesis of guanine nucleotides is responsible for maintaining the growth and differentiation of human B and T lymphocytes |
| 1.1.1.21 | aldose reductase |
drug development |
homochiral 3-hydroxy-4-substituted beta-lactams serve as precursors to the corresponding alpah-hydroxy-beta-amino acids, the enzyme might be useful insynthesis of these key components of many biologically and therapeutically important compounds |
| 1.1.1.21 | aldose reductase |
drug development |
the enzyme is a target for inhibitor design, enzyme inhibition has considerable potential for the treatment of diabetes, without increased risk of hypoglycemia |
| 1.1.1.21 | aldose reductase |
drug development |
the enzyme may be a potential drug target or vaccine candidate for schistosomes |
| 1.1.1.21 | aldose reductase |
drug development |
development of reductase inhibitors as drugs counteracting the onset of diabetic complications |
| 1.1.1.213 | 3alpha-hydroxysteroid 3-dehydrogenase (Re-specific) |
drug development |
the enzyme is a target for treatment of chronic pain in neuropathic diseases, overview |
| 1.1.1.213 | 3alpha-hydroxysteroid 3-dehydrogenase (Re-specific) |
drug development |
2'-hydroxyflavanone may be useful for clinical therapy of malignancies where AKR1C3 is overexpressed like in prostate and breast cancer |
| 1.1.1.23 | histidinol dehydrogenase |
drug development |
histidinol dehydrogenase is a suitable target for not only for Geotrichum candidum but also for related species, wherby compounds identified can serve as a valuable lead for development of novel non-classical antifungal therapy, notably against strain like Candida rapidly becoming resistant to conventional therapy |
| 1.1.1.23 | histidinol dehydrogenase |
drug development |
histidinol dehydrogenase is a target for the development of antimicrobial agents |
| 1.1.1.23 | histidinol dehydrogenase |
drug development |
histidinol dehydrogenase is a target for the development of antimicrobial agents, overview |
| 1.1.1.23 | histidinol dehydrogenase |
drug development |
L-histidinol dehydrogenase from Brucella suis is an enzyme involved in the histidine biosynthesis pathway which is absent in mammals, thus representing a very interesting target for the development of anti-Brucella agents |
| 1.1.1.25 | shikimate dehydrogenase (NADP+) |
drug development |
the enzyme can be a target for rational design of specific inhibitors, aiming at the development of antitubercular drugs |
| 1.1.1.25 | shikimate dehydrogenase (NADP+) |
drug development |
shikimate dehydrogenase is an essential protein for the biosynthesis of the chorismate end product and is a highly promising therapeutic target, especially for the discovery and development of new-generation anti-tuberculosis agents |
| 1.1.1.25 | shikimate dehydrogenase (NADP+) |
drug development |
the enzyme is a target for antibacterial drug development |
| 1.1.1.25 | shikimate dehydrogenase (NADP+) |
drug development |
the essential enzyme is a potential target for antimicrobials |
| 1.1.1.25 | shikimate dehydrogenase (NADP+) |
drug development |
the essential enzyme is a potential target for herbicides and antimicrobials |
| 1.1.1.25 | shikimate dehydrogenase (NADP+) |
drug development |
the enzyme is a promising target for antituberculosis agent development |
| 1.1.1.25 | shikimate dehydrogenase (NADP+) |
drug development |
the enzyme is a target for drug development required for Acinetobacter baumannii, a member of ESKAPE pathogens, that has emerged as an extreme drug-resistant bacterium towards most of the current generation. Acinetobacter baumannii demonstrates resistance to nearly all major classes of antibiotics, including broad-spectrum penicillins, carbapenems, cephalosporins, fluoroquinolones, aminoglycosides, tetracyclines, chloramphenicol, and colistin, especially polymixin, creating a public health threat worldwide |
| 1.1.1.252 | tetrahydroxynaphthalene reductase |
drug development |
the enzyme represents a target for the development of fungicides and antimicotics |
| 1.1.1.252 | tetrahydroxynaphthalene reductase |
drug development |
flavonoids inhibit 3HNR, which can thus be considered a potential target for flavonoid action. In addition to being a known target for different fungicides, 3HNR can also serve as an interesting and novel target for the development of antimycotics |
| 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
drug development |
the enzyme is a potential target for antimalarial drug development and chemotherapy |
| 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
drug development |
the enzyme is a target for antibacterial agents and inhibitor design |
| 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
drug development |
the enzyme is an excellent drug target in a number of pathogenic organisms |
| 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
drug development |
Escherichia coli Dxr represents a valuable model enzyme for the screening for new antimalarial compounds, since work with the Plasmodium falciparum Dxr is associated with considerably high effort due to the instability of this enzyme and the low yield of the available recombinant expression system, no major differences in the IC50 between Escherichia coli Dxr and Plasmodium falciparum Dxr |
| 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
drug development |
1-deoxy-D-xylulose-5-phosphate reductoisomerase in the nonmevalonate isoprene biosynthesis pathway is a target for developing antimalarial drugs |
| 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
drug development |
because the enzyme is absent in humans, DXR is a target for drug discovery |
| 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
drug development |
the enzyme is a target for the design of antimalarial drugs |
| 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
drug development |
enzyme DXR is a validated antimicrobial target |
| 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
drug development |
enzyme DXR is an antimicrobial target |
| 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
drug development |
the enzyme from Escherichia coli is a valuable target for the development of antimicrobial compounds |
| 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
drug development |
the enzyme from Mycobacterium smegmatis is a valuable target for the development of antimicrobial compounds |
| 1.1.1.267 | 1-deoxy-D-xylulose-5-phosphate reductoisomerase |
drug development |
the methyl erythritol phosphate (MEP) pathway represents an attractive series of targets for antibiotic design, considering each enzyme of the pathway is both essential and has no human homologues, including enzymes DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD) |
| 1.1.1.27 | L-lactate dehydrogenase |
drug development |
a selective lactate dehydrogenase inhibitor targeting the L-malate dehydrogenase function of Plasmodium falciparum and its corresponding tricarboxylic acid cycle provides an attractive therapeutic opportunity, in contrast to LDH targeting due to the functional similarity between human and parasite LDHs |
| 1.1.1.27 | L-lactate dehydrogenase |
drug development |
LDH is critically implicated in tumor growth and therefore considered to be an important target protein for antitumor metal complexes |
| 1.1.1.27 | L-lactate dehydrogenase |
drug development |
parasite LDH is a target for antimalarial compounds owing to structural and functional differences from the human isozymes |
| 1.1.1.27 | L-lactate dehydrogenase |
drug development |
LDH is a potential drug target and candidate antigen for immunodiagnosis (LDH can be recognized in serum from swine or patient infected with Taenia asiatica) and vaccine for taeniasis and viscero-cysticercosis caused by Taenia asiatica |
| 1.1.1.27 | L-lactate dehydrogenase |
drug development |
Sa-LDH-1 can become a potential drug target for antibiotics against Staphylococcus aureus |
| 1.1.1.27 | L-lactate dehydrogenase |
drug development |
the parasite enzyme is a potential target for antimalarial drugs |
| 1.1.1.282 | quinate/shikimate dehydrogenase [NAD(P)+] |
drug development |
the essential enzyme is a potential target for herbicides and antimicrobials |
| 1.1.1.3 | homoserine dehydrogenase |
drug development |
the enzyme might be a good target for anti-fungal drug development |
| 1.1.1.3 | homoserine dehydrogenase |
drug development |
HSD is an interesting metabolic target in the search for drugs with selective antifungal action and low toxicity to the host |
| 1.1.1.34 | hydroxymethylglutaryl-CoA reductase (NADPH) |
drug development |
inhibitors of HMG-CoA reductase for reducing low density lipoprotein cholesterol in the treatment of hypercholesterolemia |
| 1.1.1.34 | hydroxymethylglutaryl-CoA reductase (NADPH) |
drug development |
a yeast expression system can serve to study the influence of selected mutations in human HMG-CoA reductase on the sensitivity of the enzyme to commonly prescribed statins, thus this model system is suitable for the development and selection of lipid-lowering drugs as well as for the examination of DNA sequence variations in the context of statin therapy |
| 1.1.1.34 | hydroxymethylglutaryl-CoA reductase (NADPH) |
drug development |
overexpression of HMGR appears promising for obtaining a constant high production of artemisinin, an effective drug against malaria for which no resistant strains of Plasmodium falciparum have been reported |
| 1.1.1.357 | 3alpha-hydroxysteroid 3-dehydrogenase |
drug development |
testosterone is converted to 5alpha-dihydrotestosterone, which is present at high concentrations in patients with castration resistant prostate cancer (CRPC). Inhibition of 17beta-HSD5 is therefore considered to be a promising therapy for treating CRPC. High-throughput inhibitor screening, overview |
| 1.1.1.37 | malate dehydrogenase |
drug development |
mitochondrial malate dehydrogenase is a biological target for antiproliferative activity |
| 1.1.1.49 | glucose-6-phosphate dehydrogenase (NADP+) |
drug development |
Trypanosoma brucei G6PDH is a valid drug target for human steroids. Inhibition of G6PDH by dehydroepiandrosterone derivatives may lead to the development of a new class of anti-trypanosomatid compounds |
| 1.1.1.49 | glucose-6-phosphate dehydrogenase (NADP+) |
drug development |
the enzyme is a target for anti-parasite drug development |
| 1.1.1.50 | 3alpha-hydroxysteroid 3-dehydrogenase (Si-specific) |
drug development |
the enzyme is a target for treatment of chronic pain in neuropathic diseases, overview |
| 1.1.1.51 | 3(or 17)beta-hydroxysteroid dehydrogenase |
drug development |
the steroidogenic enzyme 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3) is a therapeutic target in the management of androgen-sensitive diseases such as prostate cancer and benign prostate hyperplasia |
| 1.1.1.62 | 17beta-estradiol 17-dehydrogenase |
drug development |
several 17beta-HSD isozymes are targets for drug development with importance in cancer, metabolic diseases, neurodegeneration and possibly immunity |
| 1.1.1.62 | 17beta-estradiol 17-dehydrogenase |
drug development |
the enzyme is considered a promising drug target against estrogen-dependent cancers |
| 1.1.1.62 | 17beta-estradiol 17-dehydrogenase |
drug development |
the enzyme constitutes an interesting therapeutic target for estrogen-dependent diseases |
| 1.1.1.64 | testosterone 17beta-dehydrogenase (NADP+) |
drug development |
testosterone is converted to 5alpha-dihydrotestosterone, which is present at high concentrations in patients with castration resistant prostate cancer (CRPC). Inhibition of 17beta-HSD5 is therefore considered to be a promising therapy for treating CRPC. High-throughput inhibitor screening, overview |
| 1.1.1.86 | ketol-acid reductoisomerase (NADP+) |
drug development |
the enzyme is a promising target for the design of herbicides |
| 1.1.1.86 | ketol-acid reductoisomerase (NADP+) |
drug development |
the enzyme is a target for herbicide drug development, computer-aided drug design |
| 1.1.1.B40 | 11beta-hydroxysteroid dehydrogenase (NAD+) |
drug development |
the enzyme is a target for inhibitor design and development |
| 1.1.3.15 | (S)-2-hydroxy-acid oxidase |
drug development |
in humans the enzyme is a potential drug target for treatment of primary hyperoxaluria, a genetic disorder where overproduction of oxalate results in the formation of kidney stones |
| 1.1.3.15 | (S)-2-hydroxy-acid oxidase |
drug development |
isozyme Hao2 is a target for drug development in high blood pressure |
| 1.1.3.6 | cholesterol oxidase |
drug development |
the cytotoxicity activity against a few cancer cell lines, while broadly sparing the normal cells, suggests the possible use of this enzyme as a promising future contender for anticancer therapy |
| 1.1.3.6 | cholesterol oxidase |
drug development |
the enzyme showed significant cytotoxicity on breast (MCF-7), nasopharyngeal (KB) and ovarian (OVCAR) cancer cell lines at very low concentrations ranging from 0.000093 to 0.00014 mM. It exhibits relatively less cytotoxicity on primary mouse embryonic fibroblast (3T3) cells. Thus, cholesterol oxidase from Streptomyces sp. AKHSS could be a potential anticancer agent |
| 1.10.3.1 | catechol oxidase |
drug development |
the enzyme is a target for development of specific inhibitors to avoid unfavorable enzymatic browning of plant-derived foods by tyrosinase causing decrease in nutritional quality and economic loss of food products |
| 1.13.11.11 | tryptophan 2,3-dioxygenase |
drug development |
the enzyme is a target for drug development |
| 1.13.11.27 | 4-hydroxyphenylpyruvate dioxygenase |
drug development |
4-hydroxyphenylpyruvate dioxygenase (HPPD), an essential enzyme in tyrosine catabolism, is an important target for treating type I tyrosinemia |
| 1.13.11.27 | 4-hydroxyphenylpyruvate dioxygenase |
drug development |
4-hydroxyphenylpyruvate dioxygenase is one of the most promising target sites for herbicide discovery |
| 1.13.11.27 | 4-hydroxyphenylpyruvate dioxygenase |
drug development |
plant 4-hydroxyphenylpyruvate dioxygenase (HPPD) is the molecular target for development of specific inhibitors |
| 1.13.11.27 | 4-hydroxyphenylpyruvate dioxygenase |
drug development |
the enzyme is a target for inhibitor and herbicide development |
| 1.13.11.27 | 4-hydroxyphenylpyruvate dioxygenase |
drug development |
the enzyme is an important target for treating type I tyrosinemia and alkaptonuria due to its significant role in tyrosine catabolism |
| 1.13.11.27 | 4-hydroxyphenylpyruvate dioxygenase |
drug development |
the human enzyme is a target for drug development in treatment of type 1 tyrosinemia, alkaptonuria, and hawkinsinuria, overvuew |
| 1.13.11.31 | arachidonate 12-lipoxygenase |
drug development |
cardiac 12/15-LOX is involved in the development of heart failure and inhibition of 12/15-LOX may be a novel treatment for this condition |
| 1.13.11.31 | arachidonate 12-lipoxygenase |
drug development |
induction of pro-carcinogenic 12-LOX pathway by an anticancer ceramide, which may be relevant to cancer biologists studying drug resistant tumors and devising potent anticancer therapeutic strategies to treat drug resistant tumors. Induction of 12-LOX pathway by ceramide may have implications in understanding pathophysiology of neurodegenerative diseases involving reactive oxygen species generation and inflammation |
| 1.13.11.31 | arachidonate 12-lipoxygenase |
drug development |
inhibition of 12/15-LOX provides robust protection against cell death preventing mitochondrial damage in oxidative stress-related brain injury |
| 1.13.11.31 | arachidonate 12-lipoxygenase |
drug development |
p12-LOX pathway may be an effective target of chemoprevention for skin carcinogenesis |
| 1.13.11.33 | arachidonate 15-lipoxygenase |
drug development |
15-LO-1 is an attractive pharmacological target for treatment of inflammatory respiratory diseases like asthma, rhinitis and chronic obstructive pulmonary disease |
| 1.13.11.33 | arachidonate 15-lipoxygenase |
drug development |
systemic delivery of cholesterol-tagged siRNAs targeting 12/15-LO has renoprotective effects under diabetic conditions and therefore can be a novel therapeutic approach for diabetic nephropathy |
| 1.13.11.33 | arachidonate 15-lipoxygenase |
drug development |
trials of 15LO1 pathway inhibitors in asthma may be a promising treatment strategy |
